Compartilhar
Informação da revista
Número
Vol. 44. Núm. S1.Páginas S1-S44 (Outubro 2022)
Speaker presentations
Will immune therapy cure acute myeloid leukemia?
Robert Peter Gale
Hematol Transfus Cell Ther. 2022;44 Supl 1:S1
Open access
Speaker presentations
Brentuximab Vedotin versus checkpoint inhibitors: Which one? When? Why should be preferred?
Murat Özbalak
Hematol Transfus Cell Ther. 2022;44 Supl 1:S1-S2
Open access
Treatment of Mantle Cell Lymphoma in Transplant Non-Eligible Patients
Valeh Huseynov
Hematol Transfus Cell Ther. 2022;44 Supl 1:S2-S3
Open access
HOW I TREAT DOUBLE-HIT LYMPHMOMA AND HGBL, NOS
Guilherme Duffles, Carmino Antonio De Souza
Hematol Transfus Cell Ther. 2022;44 Supl 1:S3
Open access
Appropriate management of Polycythemia Vera with cytoreductive drug therapy
Tiziano BARBUI
Hematol Transfus Cell Ther. 2022;44 Supl 1:S3-S4
Open access
Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
Evangelos Terpos
Hematol Transfus Cell Ther. 2022;44 Supl 1:S4-S5
Open access
Reduced Intensity Conditioning for Allogeneic Stem Cell Transplantation (HSCT) in Acute Myeloid Leukemia
Arnon Nagler
Hematol Transfus Cell Ther. 2022;44 Supl 1:S5
Open access
Lessons from the European and Israel National MDS Registry
Galia Stemer
Hematol Transfus Cell Ther. 2022;44 Supl 1:S5-S6
Open access
EMERGING DATA FOR CANCER ASSOCIATED THROMBOSIS TREATMENT
Piera Sivera
Hematol Transfus Cell Ther. 2022;44 Supl 1:S6
Open access
The Then, Now, & Future of Engineered T-Cell Therapeutics for Human Application
Bruce Levine
Hematol Transfus Cell Ther. 2022;44 Supl 1:S7-S8
Open access
FROM ALLOGENIC TRANSPLANTATION TO PRECISION IMMUNE THERAPY
Jean-François Rossi
Hematol Transfus Cell Ther. 2022;44 Supl 1:S8
Open access
XIII EHOC 2022 / CELLULAR THERAPY: CAR T-CELLS IN HEMATOLOGICAL MALIGNANCIES
Hematol Transfus Cell Ther. 2022;44 Supl 1:S8-S9
Open access
USA EXPERIENCE: IN-HOUSE PREPARATION: PROSPECTS AND PROBLEMS
Albert Donnenberg, John Lister
Hematol Transfus Cell Ther. 2022;44 Supl 1:S9
Open access
Pediatric presentations
TREATMENT OF SICKLE CELL ANEMIA
Dr. Salam Alkindi
Hematol Transfus Cell Ther. 2022;44 Supl 1:S10
Open access
EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDHOOD
Hale Ören
Hematol Transfus Cell Ther. 2022;44 Supl 1:S10-S11
Open access
SUBCUTANEOUS TREATMENT MODALITIES IN HEMOPHILIA CARE IN 2022
Peter Noun
Hematol Transfus Cell Ther. 2022;44 Supl 1:S11
Open access
STEM CELL TRANSPLANTATION IN BRAIN TUMORS
Volkan Hazar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S11
Open access
TREATMENT/MANAGEMENT OF OTHER HEPATIC TUMORS
Dildar Bahar Genc
Hematol Transfus Cell Ther. 2022;44 Supl 1:S11-S12
Open access
Oral presentations
THE ACUTE LYMPHOBLASTIC LEUKEMIA OF DOWN SYNDROME
Cemile SELIMOGLU, Sezgin PEPELER, Gulsah EFECIK, Funda CERAN, Simten DAGDAS, Gulsum OZET
Hematol Transfus Cell Ther. 2022;44 Supl 1:S13
Open access
Low Incidence of Central Nervous System (CNS) Relapse of Diffuse Large B-Cell Lymphoma despite Limited Use of Intrathecal Prophylaxis
Aamer Aleem, Farjah Algahtani, Omar Aloraini, Ahmed Jamal, Musa Alzahrani, Ghazi Alotaibi, Omar Alayed, Khalid Alsaleh
Hematol Transfus Cell Ther. 2022;44 Supl 1:S13-S14
Open access
AN UPDATED OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT
Carmino A De SOUZA, Carlos S CHIATTONE, Eliana MIRANDA, Juliana PEREIRA, Karyn Z CECYN, Nelson S CASTRO, Sergio A B BRAZIL, Danielle F C FARIAS, ... Massimo FEDERICO
Hematol Transfus Cell Ther. 2022;44 Supl 1:S14-S15
Open access
UPDATED PROGRESSION-FREE SURVIVAL (PFS) AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE (ISA-KD) VS KD IN RELAPSED MULTIPLE MYELOMA (MM)
Ozgur PEKTAS, Philippe MOREAU, Meletios-Athanasios DIMOPOULOS, Joseph MIKHAEL, Kwee YONG, Marcelo CAPRA, Thierry FACON, Roman HAJEK, ... Thomas MARTIN
Hematol Transfus Cell Ther. 2022;44 Supl 1:S15
Open access
Pediatric Acute Myeloid Leukemia (AML): NOTCH1 activation influencing prognosis through Transforming Growth Factor-B (TGF-Beta) / SETBP1; Report of a Pilot Study from Saudi Arabia
GHALEB ELYAMANY, Nawaf ALKHAYAT, Omar AL SHARIF, Yasser ELBORAI, Mohammad AL SHAHRANI, Omar ALSUHAIBANI
Hematol Transfus Cell Ther. 2022;44 Supl 1:S15-S16
Open access
EVALUATION OF COVID-19 FEAR AND QUALITY OF LIFE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING THE COVID-19 PANDEMIC
Serhat Çelik, Zeynep Tuğba Güven, Funda İpekten, Muzaffer Keklik, Ali Ünal, Leylagül Kaynar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S16
Open access
UMBILICAL CORD BLOOD (UCB) AND BONE MARROW (BM) AS A SOURCE OF NATURAL KILLERS (NK) FOR KIR-ALLOREACTIVE ADOPTIVE IMMUNOTHERAPY (KIR-AI)
Kapitolina Melkova, Gennady Frolov, Zhanna Sharoyan
Hematol Transfus Cell Ther. 2022;44 Supl 1:S16-S17
Open access
HUMORAL IMMUNITY RESPONSES AFTER VACCINATION FOR HEPATITIS B VIRUS IN AUTOGRAFTED PATIENTS: A SINGLE CENTER EXPERIENCE
Panayotis Kaloyannidis, Naeema Al Musailemelime, Abdulelah Al Shami, Manal Al Enazi, Norah Al Mulhem, Ahmed Bahrani, Rabab Attas, Solaf Kanfar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S17
Open access
ANTIBODY RESPONSES AND SAFETY OF THE COMMERCIALLY AVAILABLE VACCINES AGAINST SARS-COV-2 VIRUS IN ALLOGRAFTED PATIENTS: REAL WORLD DATA FROM A SINGLE CENTER
Panayotis Kaloyannidis, Belal Blowi, Rana Yahya, Hamdah Al Khaldi, Rabab Attas, Afra Dayel, Solaf Kanfar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S17-S18
Open access
THE MENTAL HEALTH STATUS OF INPATIENTS WITH NEWLY DIAGNOSED HEMATOLOGICAL CANCER DURING THE COVID-19 PANDEMIC
Ferda CAN, Alperen KORKMAZ, Tekin GUNEY, Sema AKINCI
Hematol Transfus Cell Ther. 2022;44 Supl 1:S18
Open access
CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS
Zeynep Tuğba GÜVEN, Muzaffer KEKLİK, Ali ÜNAL
Hematol Transfus Cell Ther. 2022;44 Supl 1:S18-S19
Open access
TREATMENT OF A PATIENT DIAGNOSED WITH ERDHEIM CHESTER'S DISEASE IN COOPERATION WITH PLASTIC SURGERY AND HEMATOLOGY
Simge ERDEM, Dilek Özden ÖZLÜK, Erol KOZANOĞLU, Sevgi KALAYOĞLU BEŞIŞIK
Hematol Transfus Cell Ther. 2022;44 Supl 1:S19
Open access
A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS; PULMONARY AL AMYLOIDOSIS
Simge ERDEM, Nigar TAGHİYEVA, Kaan AKIN, Hilal KONYAOĞLU, Sevgi KALAYOĞLU BEŞIŞIK
Hematol Transfus Cell Ther. 2022;44 Supl 1:S19
Open access
REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).
Jean-François Rossi, Emmanuel Bonnet, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, ... Emmanuel Goffart
Hematol Transfus Cell Ther. 2022;44 Supl 1:S19-S20
Open access
Immunophenotypic features of molecular subtypes of breast cancer
S.V. Chulkova, I.V. Poddubnaya, N.N. Tupitsyn
Hematol Transfus Cell Ther. 2022;44 Supl 1:S20-S21
Open access
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA – CHALLENGING ISSUES OF HEMATO-ONCOLOGY
Vasile Musteata, Larisa Musteata, Dana Coman
Hematol Transfus Cell Ther. 2022;44 Supl 1:S21
Open access
THE EFFECT OF THE COVID-19 PANDEMIC PROCESS ON TREATMENT COMPLIANCE IN HEMOPHILIA PATIENTS
Şifa Şahin, Serap Karaman, Yasin Yılmaz, Mustafa Bilici, Saadet Aslan, Hikmet Gülşah Tanyıldız, Deniz Tuğcu, Zeynep Karakaş, Ayşegül Ünüvar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S21-S22
Open access
Evaluation of MRD-status in post-induction period in pediatric patients with acute lymphoblastic leukemia.
Meri Shervashidze, Alexandra Palladina, Timur Valiev
Hematol Transfus Cell Ther. 2022;44 Supl 1:S22
Open access
Ghosal hematodiaphyseal dysplasia (GHDD) diagnosis and treatment: case report
Gular MAMMADOVA, Samira HASANOVA, Konul BAGHIROVA, Avesta ALLAHVERDIYEVA, Narmin EYVAZOVA, Adam NAJAFLI, Kamala MAMMADOVA, Afag NASIBOVA, Valeh HUSEYNOV
Hematol Transfus Cell Ther. 2022;44 Supl 1:S22-S23
Open access
Comparison of the quality of life of patients with a beta-thalassemia major, regularly receiving parenteral and oral chelators
Samira Hasanova, Azer Kerimov, Khanum Hamidova, Konul Baghirova
Hematol Transfus Cell Ther. 2022;44 Supl 1:S23
Open access
LABORATORY AND CLINICAL FEATURES OF TUMOR LYSIS SYNDROME IN CHILDREN WITH HIGH-GRADE NON-HODGKIN LYMPHOMA AND EVALUATION LONG-TERM RENAL FUNCTIONS IN SURVIVORS
Selcen BOZKURT, Dildar Bahar GENC, Sema VURAL
Hematol Transfus Cell Ther. 2022;44 Supl 1:S23-S24
Open access
IMPACT OF COVID-19 PANDEMIC ON DELAY OF CHILDHOOD CANCER DIAGNOSIS AND THE OUTCOMES IN A PEDIATRIC HEMATOLOGY/ONCOLOGY DEPARTMENT
Selma CAKMAKCI, Neriman SARI, Arzu YAZAL ERDEM, Sonay INCESOY OZDEMIR, Derya OZYORUK, Aslınur OZKAYA PARLAKAY, İnci ERGURHAN ILHAN
Hematol Transfus Cell Ther. 2022;44 Supl 1:S24
Open access
INTRAPLEURAL THERAPY TO DISRUPT IL-6/IL-8 JUXTACTINE SIGNALLING TO BLOCK TUMOR EMT AND TO DRIVE SYSTEMIC ANTI-TUMOR IMMUNITY
Vera Donnenberg, Albert Donnenberg, Ibrahim Sultan, Shannon Puhalla, James Luketich, Christie Hilton, David Bartlett
Hematol Transfus Cell Ther. 2022;44 Supl 1:S24-S25
Open access
NIVOLUMAB EXPERIENCE IN PEDIATRIC MALIGNITIES
Melek YAMAN ORTAKOYLU, Sonay INCESOY OZDEMIR, Handan DINCASLAN, Nurdan TACYILDIZ, Emel CABI UNAL
Hematol Transfus Cell Ther. 2022;44 Supl 1:S25
Open access
MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Aleksandra Palladina, Alexander Popa, Timur Valiev, Nikolay Tupitsyn
Hematol Transfus Cell Ther. 2022;44 Supl 1:S25
Open access
Evaluation of Microbiologically Documented Bloodstream Infections in Pediatric Hematology/Oncology Patients: Results of Ten Years
Zehra Aslı İŞERİ KÜSKÜ, Lütfiye ÖKSÜZ, Betigül ÖNGEN, Zeynep KARAKAŞ
Hematol Transfus Cell Ther. 2022;44 Supl 1:S25-S26
Open access
INFLUENCE OF CANCER NEWS ON QUALITY OF LIFE OF PATIENT'S FAMILIES: AN OBSERVATIONAL STUDY
Saqib Khan, Tariq Muhammad, Yasmin Abdul Rashid
Hematol Transfus Cell Ther. 2022;44 Supl 1:S26
Open access
Poster presentations
Molecular Aspects in Chronic Lymphocytic Leukemia patients with Autoimmune Cytopenias: single center experience
Sanja Trajkova, Nevenka Ridova, Marija Popova Labacevska, Aleksandra Pivkova Veljanovska, Simona Stojanovska, Dushko Dukovski, Milche Cvetanoski, Lazar Cadievski, ... Irina Panovska Stavridis
Hematol Transfus Cell Ther. 2022;44 Supl 1:S27
Open access
Follow-up of Chronic Myeloid Leukemia Patients whose Tyrosine Kinase Treatment Was Stopped: Case Series
Kemal Fidan, Ali Unal
Hematol Transfus Cell Ther. 2022;44 Supl 1:S27-S28
Open access
TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: MANAGEMENT APPROACHES
Vasile Musteata
Hematol Transfus Cell Ther. 2022;44 Supl 1:S28
Open access
PHENOTYPE/ GENOTYPE SCREENING PATTERN OF HEMOPHILIA A AND B IN SAUDI ARAB
Tarek Owaidah, Salwa Bakr, Hala AbaAlkhail, Hazza Alzahrani, Mahasen Saleh, Abdulrahman Almusa, Nouf Al-Numair, Haitham Khogeer, Faisal Al-Allaf
Hematol Transfus Cell Ther. 2022;44 Supl 1:S28-S29
Open access
SERUM LEVEL OF VASCULAR CELL ADHESION MOLECULE AND P SELECTIN AS THROMBOPHILIC RISK FACTOR FOR EARLY VASCULAR ACCESS THROMBOTIC OCCLUSION IN HEMODIALYSIS PATIENTS
Mohamed Sherif, Amr Gawaly, Heba Murad, Mohamed Dawoud, Kamal Okasha
Hematol Transfus Cell Ther. 2022;44 Supl 1:S29
Open access
SUCCESSFUL MANAGEMENT OF SEVERE CONGENITAL FACTOR X DEFICIENCY DURING PREGNANCY AND LABOR WITH PCC IN TWO SISTERS
Alfadil Haroon, Riad Elfakih, Hazzaa Alzahrani
Hematol Transfus Cell Ther. 2022;44 Supl 1:S29-S30
Open access
PREVENTION CAN BE THE BEST TOOL FOR ADULT T-CELL LEUKEMIA. UPDATED T-CELL BRAZIL PROJECT
Carmino De Sousa, Carlos Chiattone, Eliana Miranda, Yung Gonzaga, Maria Dias, Renata L R Baptista, Davimar Borducchi, Guilherme Duffles, ... Massimo Federico
Hematol Transfus Cell Ther. 2022;44 Supl 1:S30
Open access
AN UNUSUAL OCULAR LYMPHOMA, PRIMARY INTRAVITREAL LYMPHOMA DIAGNOSED INCIDENTALLY
Nur Seda Ibili Cetinkaya, Simge Erdem, Nursema Deniz, Berna Basarir, Halil Özgür Artunay, Tarık Onur Tiryaki, Ali Emre Bardak, Hazel Taş, ... Sevgi Kalayoglu Besisik
Hematol Transfus Cell Ther. 2022;44 Supl 1:S30-S31
Open access
THE RELATIONSHIP BETWEEN FERRITIN LEVEL AND THROMBOSIS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Buğra Sağlam, Murat Albayrak, Abdulkerim Yıldız, Pınar Tıplıoğlu, Mesut Tığlıoğlu, Merih Reis Aras, Fatma Yılmaz, Hacer Berna Afacan Öztürk
Hematol Transfus Cell Ther. 2022;44 Supl 1:S31
Open access
RITUXIMAB INDUCED LUNG DISEASE IN A MANTLE CELL LYMPHOMA PATIENT RECEIVING MAINTENANCE: CASE PRESENTATION
Aslı Öztürkmen, Eyyüp Akkaya, Eren Davulcu, Emine Gültürk, Fehmi Hindilerden
Hematol Transfus Cell Ther. 2022;44 Supl 1:S31
Open access
THE DIVERSITY OF PRESENTATION AND MANAGEMENT OF SUBCUTANEOUS PANNICULITIS –LIKE T-CELL LYMPHOMA WITH ASSOCIATED HEMOPHAGOCYTIC SYNDROME - CASE SERIES ANALYSIS
Agnieszka Giza, Justyna Jedras, Maria Rozploch, Ewa Czepko, Marcin Jonca, Dagmara Zimowska-Curylo, Mateusz Wilk, Malgorzata Razny, ... Tomasz Sacha
Hematol Transfus Cell Ther. 2022;44 Supl 1:S32
Open access
RELAPSED MANTLE CELL LYMPHOMA WITH ISOLATED CENTRAL NERVOUS SYSTEM INVOLVEMENT THAT TREATED WITH IBRUTINIB; A CASE REPORT AND LITERATURE REVIEW
Pinar Tiglioglu, Salih Sertac Durusoy, Melis Mutlu, Mehmet Yilmaz
Hematol Transfus Cell Ther. 2022;44 Supl 1:S32
Open access
Is there any new prognostic score for peripheral T-cell lymphoma?
D.M. Akkurd, H.H. Şahin, İ. Doğan, V. Okan
Hematol Transfus Cell Ther. 2022;44 Supl 1:S32-S33
Open access
Risk assessment for newly diagnosed, fit and young patients with Multiple Myeloma, in the era of novel treatment modalities: Are there any additional factors to be under consideration?
Panayotis Kaloyannidis, Fatema Abdulla, Enas Mutahar, Haidar Hashim, Salman Harbi, Analie Estanislao, Solaf Ka
Hematol Transfus Cell Ther. 2022;44 Supl 1:S33
Open access
LONG-TERM OUTCOMES OF PATIENTS TREATED WITH CAPLACIZUMAB FOR IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP): THE POST-HERCULES STUDY
Özgür Pektaş, Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knöbl, Flora Peyvandi, Spero Cataland, ... Julie Lin
Hematol Transfus Cell Ther. 2022;44 Supl 1:S33-S34
Open access
EFFICACY OF FUROSEMIDE IN METHOTREXATE CLEARANCE IN PATIENTS TREATED WITH HIGH DOSE METHOTREXATE
Saqib Khan, Tariq Muhammad, Yasmin Abdul Rashid
Hematol Transfus Cell Ther. 2022;44 Supl 1:S34
Open access
CART CELL THERAPY BLACK SHADOW IN HEMATOLOGICAL DISORDERS : SYSTEMIC REVIEW WITH META-ANALYSIS
Ghada EL Gohary
Hematol Transfus Cell Ther. 2022;44 Supl 1:S34-S35
Open access
RECTAL CANCER DISTANCE TO THE ANAL VERGE AND THE T STAGING: MAGNETIC RESONANCE IMAGING FINDINGS
Abdalraouf Omar, Fatma Algledy, Najat Amar, Mufeida Elmusrati
Hematol Transfus Cell Ther. 2022;44 Supl 1:S35
Open access
A CASE OF FASCIOLOSIS PRESENTING WITH SEVERE HYPEREOSINOPHILIA
Metban Mastanzade, Arzu Şenol, Alper Koç
Hematol Transfus Cell Ther. 2022;44 Supl 1:S35
Open access
RITUXIMAB-INDUCED SEVERE ACUTE THROMBOCYTOPENIA IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA
Taha Ulutan Kars, Zahit Furkan Yorgancı, Osman Yaşkıran, Atakan Tekinalp
Hematol Transfus Cell Ther. 2022;44 Supl 1:S35-S36
Open access
VITAMIN B 12 DEFICIENCY MIMICKING THROMBOTIC MICROANGIOPATHY: A CASE REPORT
Müzeyyen Aslaner Ak, Selime Yiğit, Gizem Süren, Şehmus Ertop
Hematol Transfus Cell Ther. 2022;44 Supl 1:S36
Open access
QUALITY OF LIFE IN HEMATOLOGICAL PATIENTS IN THE POST-COVID ERA
Weronika Lebowa, Karol Miklusiak, Ositadima Chukwu, Agnieszka Giza, Tomasz Sacha
Hematol Transfus Cell Ther. 2022;44 Supl 1:S36-S37
Open access
ECULIZUMAB DOSE ADJUSTMENTS DURING PREGNANCIES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A SINGLE CENTER EXPERIENCE.
Semra Aydin, Valentina Giai, Stefano D'ardia, Giorgia Iovino, Chiara Frairia, Irene Urbino, Marco Cerrano, Eloise Beggiato, Ernesta Audisio
Hematol Transfus Cell Ther. 2022;44 Supl 1:S37
Open access
ALECTINIB-RELATED ERYTHROCYTE MEMBRANE CHANGES, NON-IMMUNE HEMOLYSIS AND ERYPTOSIS
Emine Gulturk
Hematol Transfus Cell Ther. 2022;44 Supl 1:S37
Open access
GLOMERULAR MICROANGIOPATHY WITH MARKED SYSTEMIC THROMBOTIC MICROANGIOPATHY SHORTLY AFTER BORTEZOMIB IN A NEWLY DIAGNOSED POEMS SYNDROME PATIENT
Tarık Onur Tiryaki, Akın Işık, Simge Erdem, Nurana Güller, Gamze Kemeç, Halil Yazıcı, Yasemin Özlük, Işın Kılıçaslan, Sevgi Kalayoğlu Beşışık
Hematol Transfus Cell Ther. 2022;44 Supl 1:S38
Open access
THE SUCCESSFUL MAJOR SURGERY IN A PATIENT WITH INHERITED FVII DEFICIENCY AND A HUGE NASOPHARYNGEAL ANGIOFIBROMA
Aysegul Unuvar, Levent Aydemir, Mehmet Barburoglu, Sifa Sahin, Mustafa Bilici, Deniz Tugcu, Gulsah Tanyildiz, Zeynep Karakas, Serap Karaman
Hematol Transfus Cell Ther. 2022;44 Supl 1:S38
Open access
ROLE OF SERUM HEPCIDIN AND RETICULOCYTE HEMOGLOBIN CONCENTRATION IN EVALUATION OF ANEMIA IN ULCERATIVE COLITIS PATIENTS
Amr Mohamed Gawaly Gawaly, Samar Ammar, Medhat Ghazy, Maaly Mabrouk
Hematol Transfus Cell Ther. 2022;44 Supl 1:S39
Open access
GRISCELLI SYNDROME TYPE 2 –CLINICAL APPROACH AND CASE REPORT
Konul Baghirova, Gular Mammadova, Avesta Allahverdiyeva, Narmin Eyvazova, Narmin Verdiyeva, Agarza Agayev, Samira Hasanova, Valeh Huseynov
Hematol Transfus Cell Ther. 2022;44 Supl 1:S39
Open access
THE COURSE OF TOXIC HEPATITIS IN LEUKEMIC PATIENTS AT THE STAGE OF SUPPORT THERAPY.
Mireldar Babayev, Ahmadova Afaq
Hematol Transfus Cell Ther. 2022;44 Supl 1:S39-S40
Open access
RARE UNSTABLE ALPHA GLOBIN VARIANT HB TAYBE (HBA1:C.118_120DELACC) WITH HBA2 POLY A MUTATIONS, CAUSES TO HEMOLYTIC ANEMIA IN TWO CASES FROM AZERBAIJAN
AghaRza Aghayev, Khuraman Jafarova, Afsana Mammadova, Zenfira Mirzeyeva, Valeh Huseynov
Hematol Transfus Cell Ther. 2022;44 Supl 1:S40-S41
Open access
HBH DISEASE AND SYSTEMIC LUPUS ERYTHEMATOSUS
Valeh Huseynov, Afag Nasibova, Sevinj Nabiyeva
Hematol Transfus Cell Ther. 2022;44 Supl 1:S41
Open access
EVALUATION OF CLINICAL AND LABORATORY FINDINGS OF THERAPEUTIC PLASMAPHERESIS IN CHILDREN
Buğra Tutun, Defne AY Tuncel, Seda Turgut, İlknur Arslan
Hematol Transfus Cell Ther. 2022;44 Supl 1:S41-S42
Open access
NON-HODGKIN'S LYMPHOMA: A RETROSPECTIVE ASSESSMENT OF CLINICAL FEATURES AND TREATMENT OUTCOMES
Zeynep Deniz Tutun, Ganiye Begül Küpeli, Buğra Tutun
Hematol Transfus Cell Ther. 2022;44 Supl 1:S42
Open access
SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST
Melek Yaman Ortakoylu, Dilvin Celik Ates, Hale Kivrak, Isinsu Kuzu, Sonay Incesoy Ozdemir, Handan Dincaslan, Nurdan Tacyildiz, Emel Cabi Unal
Hematol Transfus Cell Ther. 2022;44 Supl 1:S42
Open access
SYNOVIAL SARCOMA ARISING IN THE RETROMOLAR TRIGONE: A RARE PRESENTATION
Asma Saleem
Hematol Transfus Cell Ther. 2022;44 Supl 1:S43
Open access
ASSOCIATION OF NF-1 AND MOYAMOYA SYNDROME : CASE REPORT
Serap Karaman, Şifa Şahin, Edibe Pembegül Yıldız, Hikmet Gülşah Tanyıldız, Mehmet Barburoğlu, Tutku Turgut, Yasin Yılmaz, Zeynep Karakaş, ... Ayşegül Ünüvar
Hematol Transfus Cell Ther. 2022;44 Supl 1:S43
Open access
EVALUATION AND MANAGEMENT OF THYROID NODULES AT A TERTIARY CARE PEDIATRIC CANCER CENTER IN TURKEY
Seda Şahin, Derya Özyörük, Arzu Yazal Erdem, Neriman Sarı, Aylin Kılınç Uğurlu, Mehmet Boyrazoğlu, Selma Çakmakcı, İnci Ergürhan İlhan
Hematol Transfus Cell Ther. 2022;44 Supl 1:S43-S44
Open access
TRAMETINIB EXPERIENCE IN A BRAF P.N 486 _P490DEL MUTATION POSITIVE LANGERHANS CELL HISTIOCYTOSIS
Sevim Gencel Karaaslan, Gül Hatice Erkol Tuncer, Melek Yaman Ortakoylu, Sonay Incesoy Ozdemir, Handan Dincaslan, Nurdan Tacyildiz, Ömer Suat Fitoz, Koray Ceyhan, ... Emel Cabi Unal
Hematol Transfus Cell Ther. 2022;44 Supl 1:S44
Open access
SERUM TOTAL OXIDANT AND ANTIOXIDANT STATUS IN CHILDREN WITH CANCER
Yasin Yilmaz, Handan Dincaslan, Sonay Ozdemir, Hatice Tuncer, Bugra Tanrioveri, Hatice Busra Kutukcu, Nurdan Tacyildiz, Emel Unal
Hematol Transfus Cell Ther. 2022;44 Supl 1:S44
Open access
Conteúdo especial sobre COVID-19
Publicar em
Hematology, Transfusion and Cell Therapy
A revista pertence ao Committee on Publication Ethics (COPE) www.publicationethics.org e adere aos seus princípios e procedimentos.